Dose adjustments and treatment discontinuations
| . | 140 mg once daily (N = 157) . | 70 mg twice daily (N = 159) . |
|---|---|---|
| Median daily dose, mg (range) | 138.0 (20.0-216.0) | 110.0 (20.0-178.0) |
| Interruption, n (%) | ||
| Hematologic toxicity | 40 (25) | 47 (30) |
| Nonhematologic toxicity | 48 (31) | 61 (38) |
| Reduction, n (%) | ||
| Hematologic toxicity | 29 (18) | 30 (19) |
| Nonhematologic toxicity | 27 (17) | 44 (28) |
| Escalation, n (%) | 52 (33) | 39 (25) |
| Still on therapy, n (%) | 54 (34) | 56 (35) |
| Discontinued therapy, n (%) | ||
| Disease progression | 39 (25) | 32 (20) |
| Study drug toxicity | 32 (20) | 39 (25) |
| Adverse event unrelated to study drug | 9 (6) | 7 (4) |
| Investigator request | 6 (4) | 5 (3) |
| Patient request | 4 (3) | 5 (3) |
| Proceeding to stem cell transplantation | 2 (1) | 9 (6) |
| Lack or loss of response | 6 (4) | 2 (1) |
| Anemia/thrombocytopenia | 1 (< 1) | 0 (0) |
| Death | 1 (< 1) | 0 (0) |
| Development of mutation | 2 (1) | 2 (1) |
| Protocol violation | 1 (< 1) | 0 (0) |
| Poor compliance | 0 (0) | 1 (< 1) |
| Pregnancy | 0 (0) | 1 (< 1) |
| . | 140 mg once daily (N = 157) . | 70 mg twice daily (N = 159) . |
|---|---|---|
| Median daily dose, mg (range) | 138.0 (20.0-216.0) | 110.0 (20.0-178.0) |
| Interruption, n (%) | ||
| Hematologic toxicity | 40 (25) | 47 (30) |
| Nonhematologic toxicity | 48 (31) | 61 (38) |
| Reduction, n (%) | ||
| Hematologic toxicity | 29 (18) | 30 (19) |
| Nonhematologic toxicity | 27 (17) | 44 (28) |
| Escalation, n (%) | 52 (33) | 39 (25) |
| Still on therapy, n (%) | 54 (34) | 56 (35) |
| Discontinued therapy, n (%) | ||
| Disease progression | 39 (25) | 32 (20) |
| Study drug toxicity | 32 (20) | 39 (25) |
| Adverse event unrelated to study drug | 9 (6) | 7 (4) |
| Investigator request | 6 (4) | 5 (3) |
| Patient request | 4 (3) | 5 (3) |
| Proceeding to stem cell transplantation | 2 (1) | 9 (6) |
| Lack or loss of response | 6 (4) | 2 (1) |
| Anemia/thrombocytopenia | 1 (< 1) | 0 (0) |
| Death | 1 (< 1) | 0 (0) |
| Development of mutation | 2 (1) | 2 (1) |
| Protocol violation | 1 (< 1) | 0 (0) |
| Poor compliance | 0 (0) | 1 (< 1) |
| Pregnancy | 0 (0) | 1 (< 1) |